

091-20107fn

For Internal Use Only	Submit 1 Original	OMB Approval No.:
Sec File No. 91 - RECEIVED	and 9 Copies	Expires:
Estimated average burden hours per response: 2.00		

2016 FEB 10 11 34 AM  
SEC / TM

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549  
**FORM 19b-4(e)**

Information Required of a Self-Regulatory Organization Listing and Trading a New  
Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934

**READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM**

**Part I Initial Listing Report**

1. Name of Self-Regulatory Organization Listing New Derivative Securities Product:  
**NYSE Arca, Inc. (trading pursuant to unlisted trading privileges)**

**SEC  
Mail Processing  
Section**

2. Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.):  
**Open-end Management Investment Company**

**FEB 11 2016**

3. Class of New Derivative Securities Product:  
**Investment Company Units**

**Washington DC  
404**

4. Name of Underlying Instrument:  
**Market Vectors US Listed Pharmaceutical 25 Index**



5. If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-Based:  
**Narrow-Based**

**16000136**

6. Ticker Symbol(s) of New Derivative Securities Product:  
**PPH**

7. Market or Markets Upon Which Securities Comprising Underlying Instrument Trades:  
**NYSE, NASDAQ**

8. Settlement Methodology of New Derivative Securities Product:  
**Regular way trades settle on T+3/Book entry only held in DTC.**

9. Position Limits of New Derivative Securities Product (if applicable):  
**Not applicable.**

**Part II Execution**

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form:  
**Martha Redding**

Title:  
**Senior Counsel and Assistant Secretary**

Telephone Number:  
**(212) 656-2938**

Manual Signature of Official Responsible for Form:

February 8, 2016

SEC 2449 (1/99)

Act	34
Section	
Availability:	<b>FEB 11 2016</b>



Martha Redding  
Senior Counsel  
Assistant Secretary

New York Stock Exchange  
11 Wall Street  
New York, NY 10005  
T + 1 212 656 2938  
F + 1 212 656 8101  
Martha.Redding@theice.com

RECEIVED  
SEC / TM

Via Overnight Mail

February 8, 2016

Ms. Gail Jackson  
US Securities and Exchange Commission  
Division of Trading and Markets  
Station Place - Building I  
100 F Street, N.E. - Room 6628  
Washington, DC 20549

SEC  
Mail Processing  
Section  
FEB 11 2016  
Washington DC  
404

Re: 19b-4(e) - Transmittal

Dear Ms. Jackson:

Enclosed for filing pursuant to Section 19(b) of the Securities Exchange Act of 1934 and Rule 19b-4 thereunder, please find an original and nine copies of Form 19b-4(e) with respect to the securities listed below.

- Market Vectors Biotech ETF (BBH)
- Market Vectors Pharmaceutical ETF (PPH)
- iShares 20+ Year Treasury Bond ETF (TLT)
- iShares MSCI China ETF (MCHI)
- iShares MSCI EAFE Small-Cap ETF (SCZ)
- iShares Core MSCI Total International Stock ETF (IXUS)
- iShares Global Infrastructure ETF (IGF)
- iShares Asia 50 ETF (AIA)
- iShares MSCI Brazil Small-Cap ETF (EWZS)
- iShares MSCI New Zealand Capped ETF (ENZL)
- iShares 0-5 Year Investment Grade Corporate Bond ETF (SLQD)
- iShares Morningstar Mid-Cap Value ETF (JKI)
- iShares MSCI Eurozone ETF (EZU)

If you have any questions, please do not hesitate to call me at (212) 656-2938.

Sincerely,

Enclosures

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	FEB 11 2016